News for Agios Pharmaceuticals, Inc. (AGIO)

Operator: Good morning, and welcome to Agios' Fourth Quarter 2024 Conference Call. [Operator Instructions] Please be advised that this call is being recorded at Agios' request.

On December 31, 2024, BB Biotech AG executed a significant transaction involving Agios Pharmaceuticals Inc. The firm reduced its holdings by 515,642 shares at a

Insightful Analysis of Jefferies Group (Trades, Portfolio)'s Fourth Quarter 2024 13F Filing Jefferies Group (Trades, Portfolio) recently submitted its 13F fili

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ETCompany ParticipantsBrian Goff - CEOSarah Gheuens -...

The following slide deck was published by Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -0.58% and 11.76%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

”“ ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused ”“ ”“ Safe

”“ Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha-

Agios Pharma submitted a sNDA to the FDA after two Phase III trials studying PYRUKYND (mitapivat) in thalassemia met their primary endpoints. Read more here.

We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside Potential. In this article, we are going to take a look at where Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Inc (AGIO), a leader in cellular metabolism and pyruvate kinase activation, has announced significant milestones and strategic plans for 2

”“ FDA Accepted Agios' Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent

Agios Pharmaceuticals, Inc. (AGIO), on Wednesday, announced that its supplemental New Drug Application seeking approval for the expanded use of PYRUKYND, for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, has been accepted for review by the FDA.

**media[509164]**

January 1, 2024 ”“ (Maple Hill Syndicate) ”“ The Robot Portfolio returned more than 22% last year but was edged out by the surging Standard & Poor's 500.Each

Agios Pharmaceuticals Inc (AGIO), a pioneering leader in cellular metabolism and PK activation therapies for rare diseases, announced that its management team w

**media[504848]**

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025